Rucaparib now available via the Cancer Drugs Fund

[OvacomeSupport]

Hello

This is to let you know that the PARP inhibitor rucaparib has been approved by NICE for use in the Cancer Drugs Fund. It can now be offered to people with relapsed ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy.

You can read more at independent.co.uk/news/heal...

Your treating team will be able to advise you about whether rucaparib would be suitable for you. If there's anything we can help with, please get in touch with our Support Service on 0800 008 7054 or by email at [e-mail].

Best wishes

Julia (Support Services Officer)

[Hidden]

This is very welcome good news, especially as it is available to non BRCA ladies, and you can still have it if you only had a partial response to Platinum.

[GillP100]

Thank you for the information. Is this approval subject to the same conditions as Niraparib -- i.e., that it must be started within 12 weeks of finishing successful platinum chemo? Does it depend on BRCA or other genetic indicator? Gill

[OvacomeSupport Partner My Ovacome Team in reply to GillP100]

Hello Gill

The recommendation is that it is started within 8 weeks of chemotherapy, when someone has responded to platinum chemotherapy. It isn't dependent on BRCA status. You can read the NICE final appraisal document here: nice.org.uk/guidance/gid-ta...

Do get in touch if you have any questions.

Best wishes

Anna

Ovacome Support